Changes in Body Fat Measured by DEXA in Patients Taking Different Formulations of Stavudine

REFERENCES

• Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361 (9359):726–735.
   PubMed Web of Science ®Google Scholar
• Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM. Lipodys-trophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. 2001;24(3):157–166.
   PubMed Web of Science ®Google Scholar
• Strauch B, Baum T, Robbins N. Treatment of human immu-nodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstr Surg. 2004;113(1):363–370; discussion 371–362.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Casula M, Weverlingz GJ, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allo-cated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9(3):385–393.
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: re-sults of a substudy from a comparative trial. AIDS. 2002 ;16(18):2447–2454.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Paulsen DM, Lonergan JT, et al. Improve-ments in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS. 2005;19(1):15–23.
   PubMed Web of Science ®Google Scholar
• Moyle G, Sabin C, Cartledge J, et al. A 48-week, random-ized, open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston, Massachusetts. Abstract 44LB.
   Google Scholar
• Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288(2):207–215.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Ward DJ, Hessenthaler SM, et al. Improve-ment in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38(2):263–270.
   PubMed Web of Science ®Google Scholar
• Kaul S, Damle B, Gale J, et al. Pharmacokinetics (PK) of stavudine (d4T) extended release formulation compared with stavudine immediate release (IR) formulation as part of potent antiretroviral combination therapy. In: Program and abstracts of the 9th Conference on Retroviruses and Op-portunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 430.
   Google Scholar
• White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001 ;77(3):158–173.
   PubMed Web of Science ®Google Scholar
• Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis. 2005;191 (10):1686–1696.
   PubMed Web of Science ®Google Scholar
• Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS. 2004;18(16):2127–2136.
   PubMed Web of Science ®Google Scholar
• Cherry CL, Lal L, Thompson KA, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2005;38(3):263–267.
   PubMed Web of Science ®Google Scholar
• Baril JG, Pollard RB, Raffi F, Whelden M, Rutkiewicz V, Brett-Smith H. Stavudine extended/prolonged release (XR/ PRC) vs stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety. In: Program and abstracts of the 14th International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract LbPeB9014.
   Google Scholar
• Pollard RB, Lye P, Farthing C, Whelden M, Thompson S, Brett-Smith H. Stavudine XR vs stavudine IR as part of potent antiretroviral combination therapy: 24-week safety and antivi-ral efficacy. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, Washington. Abstract 411–W.
   Google Scholar
• Hurst M, Noble S. Stavudine: an update of its use in the treatment of HIV infection. Drugs. 1999;58(5):919–949.
   PubMed Web of Science ®Google Scholar
• Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A ran-domized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med. 1997;126(5):355–363.
   PubMed Web of Science ®Google Scholar
• Brett-Smith HM, Reynolds L, Bessen LV. Two year analysis of stavudine extended-release/prolonged release capsules (XR/PRC) as compared to stavudine immediate-release (IR): efficacy and safety. In: Program and abstracts of the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd ICAAC); September 14–17, 2003; Chicago, IL. Abstract H–855b.
   Google Scholar
• Yang Y, Zhu WDJ, Paton NI. Comparison of dual-energy X-ray absorptiometry machines for measuring fat distribution changes of HIV-associated lipodystrophy. Antivir Ther. 2004;9(5):771–778.
   PubMed Web of Science ®Google Scholar
• Noor M, Dezii C, McLaren C, et al. Baseline triglyceride levels predict development of lipoatrophy in patients treated with stavudine extended-release/prolonged-re-lease capsules or stavudine immediate-release. In: Pro-gram and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Francisco. Abstract 722.
   Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syn-drome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13(13):1659–1667.
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb. Letter to A1455-1110 investigators, February 15, 2005.
   Google Scholar
• Mallon PW, Miller J, Cooper DA, Carr A. Prospective evalu-ation of the effects of antiretroviral therapy on body com-position in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971–979.
   PubMed Web of Science ®Google Scholar
• Smith DE, Hudson J, Martin A, et al. Centralized assess-ment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials. 2003;4(1):45–49.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a Public Health Approach. 2003 revision. Geneva: World Health Organization. Available at: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf. Accessed July 10,2005.
   Google Scholar